MedWatch

Biogen's US Alzheimer's drug may also come to Europe

An aging population means Aduhelm could also be approved in Europe, Senior Analyst Søren Løntoft Hansen says.

Photo: Ritzau Scanpix/Reuters/Brian Snyder

After being approved by the US Food and Drug Administration (FDA), there is a good chance that Biogen's Alzheimer's drug will also be approved in Europe, Sydbank Senior Analyst Søren Løntoft Hansen says.

The FDA has approved Biogen's Alzeheimer's treatment Aduhelm for use in the US, but it has not been approved in Europe, though there is a good chance this will happen, says Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs